JAK3

(redirected from Janus kinase 3)
Also found in: Wikipedia.

JAK3

A gene on chromosome 19p13.1 that encodes a member of the Janus kinase (JAK) family of tyrosine kinases, which are involved in cytokine-receptor-mediated intracellular signal transduction. JAK3 is primarily expressed in immune cells and transduces a signal in response to activation via tyrosine phosphorylation by interleukin receptors.

Molecular pathology
JAK3 mutations are linked to autosomal severe combined immunodeficiency disease (SCID).
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Pfizer announced results from its Phase 2a study of PF-06651600, an oral Janus kinase 3 inhibitor, and PF-06700841, a tyrosine kinase 2/JAK1 inhibitor, compared to placebo, in patients with moderate to severe alopecia areata, an autoimmune disease characterized by hair loss and often associated with profound psychological consequences.
MYOS has chosen Cloud Pharmaceuticals to start synthesis and design for small molecules relevant to Furin regulation and Janus Kinase 3 (JAK3) inhibition.
They identified mutations in the Janus kinase 3 (JAK3) gene that seemed to have a major role in driving the cancer in a significant number of patients.
Vertex Pharmaceuticals Incorporated (Cambridge, MA) has patented human Janus Kinase 3 (JAK3) and JAK3-like binding pockets.
Pfizer's investigational oral Janus kinase 3 inhibitor PF-06651600 received Breakthrough Therapy designation from the FDA for the treatment of patients with alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body.
SNA-125 selectively inhibits Janus kinase 3, or JAK3, and tropomyosin receptor kinase A, or TrkA.